Carol Moreno, MD, PhD Hematologist, University of Barcelona, discusses Outcomes From The iLLUMINATE Trial. At The 60th ASH Annual Meeting…
Browsing: Chronic Lymphocytic Leukemia
Jeff Sharman, MD Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses…
Rod A. Humerickhouse, MD, PhD Group Project Leader, Oncology Development, AbbVie, discusses Recent Advancements In The Treatment Of CLL. At…
Carol Moreno, M.D., PhD Hematologist, University of Barcelona Discusses MRD As A Legitimate Surrogate Marker In CLL At The 60th…
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology &…
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology &…
Kanti Rai, M.D. Professor of medicine at The Karches Center for Oncology Research, The Feinstein Institute for Medical Research; director…
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Monotherapy In CLL At The 60th ASH Annual…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Ongoing Trials For CLL Patients At The 60th ASH Annual Meeting…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Advances In New Cancer Regiments At The 60th ASH Annual Meeting…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Venetoclax & Carfilzomib Dose Escalation Study At The 60th ASH Annual…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Phase 3 MURANO Trial At The 60th ASH Annual Meeting on…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Benefits Of Venetoclax Studies At The 60th ASH Annual Meeting on…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Neil E. Kay, M.D., Professor of Medicine at the Mayo Clinic College of Medicine and a Consultant in the Department…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7308 In this Key Insights activity, Drs. Morton Coleman and Richard R. Furman discuss CLL-related highlights from Lymphoma…
Pierluigi Porcu, MD, from the Sidney Kimmel Cancer Center, Philadelphia, PA, discusses recent clinical developments that have provided healthcare professionals…
With new targets identified over the past few years, the development of precision medicine has expanded significantly. Speaking from the…
With cutaneous T-cell lymphoma (CTCL) being a rare disease with an incredibly high prevalence, Pierluigi Porcu, MD, from Sidney Kimmel…
At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu from Sidney Kimmel Cancer Center,…
Achieving measurable residual disease (MRD) negativity after completing therapy is an early indicator of overall survival. Presently, MRD testing is…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Barbara Eichhorst from the University Hospital Cologne, Cologne, Germany,…
Triple combination therapy is the administration of obinutuzumab, ibrutinib, and venetoclax in a sequential order. Barbara Eichhorst from the University…
Barbara Eichhorst from the University Hospital Cologne, Cologne, Germany, presents results from clinical trials testing an intensive fludarabine, cyclophosphamide, rituximab…
FCR chemoimmunotherapy is most effective in the IGVH mutated, non-17p deletion chronic lymphocytic leukemia (CLL) patient subgroup. With the advent…
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the…
First line therapies for chronic lymphocytic leukemia (CLL) have developed beyond the historic approach of giving all patients FCR chemoimmunotherapy.…
Exciting updates on obinutuzumab were presented at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm,…
The MURANO study (NCT02005471) is a Phase III trial looking at rituximab in combination with either bendamustine or venetoclax for…
While the outcome for patients with chronic lymphocytic leukemia (CLL) has significantly improved over the last 30 years due to…
Achievement of a complete response and measurable residual disease (MRD) negativity are associated with improved survival in chronic lymphocytic leukemia…
In this video, Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, presents the first interim analysis of the…
Measurable residual disease (MRD) negativity is an important treatment endpoint for many hematological malignancies and has the potential to be…
In this video, Lydia Scarfò, MD, of Vita-Salute San Raffaele University, Milan, Italy, describes the studies on chronic lymphocytic leukemia…